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COVID-19	research:	are	we	moving	too	fast?
While	getting	new	information	on	COVID-19	is	essential,	not	all	research	will	be	critical	to	managing
the	risks	of	the	disease,	writes	Peter	Howley.	He	argues	that	scientists	need	to	ensure	as	best	they
can	that	they	get	the	balance	between	accuracy	and	speed	right.
There	has	been	an	enormous	volume	of	important	COVID-19	research	coming	out	into	the	public
domain	This	includes	studies	aimed	at	calculating	case	fatalities,	effectiveness	of	new	treatments,	risk	profiles,	and
effectiveness	of	mitigation	strategies.	One	can	understand	why	—	there	is	an	insatiable	appetite	and	need	for
information	about	the	novel	coronavirus,	and	a	promise	of	not	only	much	publicity	for	any	research	findings	on	the
topic	but	also	the	hope	that	such	research	can	make	an	immediate	difference	in	people’s	lives	by	helping	to
determine	the	best	response	to	this	pandemic.	That	being	said,	a	degree	of	caution	is	needed	when	it	comes	to	the
dissemination	of	new	findings.
Existing	problems	with	publishing
It	is	not	uncommon	for	scientists	to	spend	months,	if	not	years,	carefully	developing	an	idea	into	a	paper	but	we	are
seeing	an	increasing	number	of	instances	where	the	whole	process	takes	a	matter	of	days.	Bias	towards	publishing
research	with	‘sexy’	findings	often	facilitated	by	problems	in	the	research	design,	such	as	small	samples	and	the
winners	curse,	multiple	comparisons,	and	selective	reporting	of	results	have	been	the	source	of	much	discussion.
There	are	a	small	number	of	exceptions	but	it	is	generally	the	result	of	misinformation	coupled	with	cognitive	biases
such	as	confirmation	bias	which	we	are	all	susceptible	too	(e.g.	we	tend	to	only	see	the	evidence	we	want	to	see)
rather	than	any	malfeasance.	There	are	also	signs	that	such	problems	are	beginning	to	be	taken	more	seriously	by
scientists	across	all	disciplines.
The	pandemic	has	intensified	the	above	issues,	however,	as	not	only	are	researchers	rushing	to	write	papers,	but
journals	are	also	rushing	to	publish	them	with	an	expedited	peer	review	process.	Of	course	it	is	important	to	get
good	science	on	an	important	topic	out	into	the	public	domain	as	quickly	as	possible	but	this	does	make	an	already
unpredictable	peer	review	process	even	noisier	than	usual.	While	good	science	has	been	key	to	shaping	our
response	to	the	pandemic,	research	undertaken	and	published	with	great	haste	has	the	potential	to	cause	harm.
Potential	for	harm
As	an	example,	a	study	published	in	The	Lancet	and	subsequently	retracted	purported	to	show	that
hydroxychloroquine,	far	from	being	a	successful	treatment	for	COVID-19	as	initially	hoped,	was	actually	associated
with	increased	risk.	This	led	to	the	World	Health	Organization	suspending	relevant	clinical	trials.	The	lack	of
transparency	by	the	firm	that	supplied	the	data	used	in	this	study	led	to	many	questions	surrounding	the	credibility
of	the	conclusions	–	questions	that	can	be	difficult,	if	not	impossible	for	editors	to	pick	up	prior	to	publication.	Still,	it
seems	reasonable	to	suggest	that	given	the	many	evident	methodological	concerns	in	the	paper	it	would	ordinarily
have	been	rejected	by	an	established	journal	under	a	‘normal’	peer	review	process.	That	it	had	nevertheless	been
published	has	been	used	by	some	as	a	means	to	undermine	trust	in	science.
A	further	example	was	a	study	released	to	the	media	as	a	preprint	(which	opens	up	another	set	of	problematic
issues).	Through	Facebook	ads,	the	authors	recruited	a	sample	of	3,330	residents	and	tested	them	for	COVID-19
antibodies.	It	was	an	ambitious	and	timely	study	and	argued	that	its	subsequent	analysis	suggested	that	the
background	rate	of	infection	was	much	higher	than	what	people	had	previously	thought.	This,	in	turn,	indicated	that
the	fatality	rate	may	be	substantially	lower	than	previous	best	estimates.	These	findings	were	seized	on	by
conservative	activists	in	the	US	as	evidence	against	lockdowns	and	other	mitigation	efforts.	This	kind	of	damage
was	done,	despite	a	good	deal	of	criticism	from	other	scientists	pointing	out	that	the	findings	are	most	likely	the
result	of	various	sources	of	statistical	error.	A	further	methodological	hurdle	is	selection	bias.	While	many	people
would	likely	want	an	antibody	test,	which	group	is	likely	to	go	to	greater	effort	(e.g.	travel	to	a	testing	site	etc.)	to
obtain	one?	Likely	those	who	had	good	reason	to	suspect	that	they	or	someone	close	to	them	had	the	virus.	This
means	that	instead	of	testing	a	‘representative’	sample	of	the	population	in	Santa	Clara	for	antibodies,	you	end	up
testing	a	sample	of	the	population	who,	all	things	considered,	are	more	likely	to	have	been	infected	in	the	first
place.	It	is	worth	noting	that	since	its	release	on	11	April,	the	paper	has	already	been	cited	135	times,	which	gives	a
sense	of	the	scale	and	rapid	nature	of	research	in	this	area.
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My	aim	is	not	to	be	overly	critical	of	any	particular	paper	as	methodological	and	sampling	issues	are	common,	there
is	always	uncertainty	in	observational	data,	and	there	is	no	such	thing	as	a	perfect	study.	Rather,	my	aim	is	to
highlight	that	while	researchers	are	understandably	keen	to	make	a	positive	contribution,	there	can	be	a	cost	to
jumping	out	with	new	research	findings	without	taking	the	necessary	time	to	scrutinise	the	work.
Overreach
Another,	less	serious	example	is	an	article	discussed	in	The	Telegraph	which	suggested	that	baldness	could	predict
the	severity	of	disease.	The	evidence	for	this	assertion	is	a	study	of	122	patients	in	hospitals	in	Madrid	where	it	was
found	that	male	patients	had	a	somewhat	higher	background	rate	of	baldness	than	what	would	be	expected	from
men	of	a	similar	age	in	the	population	at	large.
While	I	cannot	say	that	baldness	will	not	turn	out	to	be	a	predictor	of	disease	risk,	what	I	can	say	is	that	a	small
scale	observational	study	of	122	patients	provides	no	evidence	one	way	or	the	other.	To	see	why,	one	must
consider	just	how	variable	observational	studies	are.	If	I	look	at	any	group	of	122	patients	I	will	likely	find	that	they
differ	from	the	population	at	large	on	a	myriad	of	factors	unrelated	to	the	disease.	They	could,	for	example,	sleep
more/less,	eat	more	processed	meats,	drink	more	red	wine	or	perhaps	drink	less	white	wine.	If	I	did	uncover	a
statistically	significant	pattern,	with	the	exception	of	the	first	example,	it	would	not	be	too	difficult	to	come	up	with	a
‘causal’	explanation	to	explain	its	relevance	to	coronavirus	(e.g.	medicinal	properties	of	red	wine)	and	therein	lies
the	crux	of	the	problem.
Another	related	example	are	a	number	of	studies	(e.g.	here	and	here)	which	suggest	that	Vitamin	D
supplementation	might	play	an	important	role	in	managing	disease	risk.	These	studies	essentially	compare	mean
Vitamin	D	levels	with	Covid-19	mortality	across	countries	in	the	EU.	Somewhat	counter-intuitively,	European
countries	at	higher	latitude	have	higher	Vitamin	D	levels	despite	less	UVB	sunlight	exposure	as	fortification	of	foods
and	supplementation	is	more	common.	At	the	time	the	studies	were	published	(things	have	now	changed),	lower
latitude	countries	such	as	Spain	and	Italy	had	higher	mortality	rates	from	Covid-19	and	also	lower	mean	Vitamin	D
levels.	In	contrast	to	the	example	relating	to	baldness,	I	would	not	be	surprised	if	clinical	trials	in	future	do	show	that
Vitamin	D	is	important	at	least	to	some	degree	but	again	what	I	can	say	is	that	studies	of	this	nature	provide	no	real
evidence	one	way	or	the	other.	These	countries	may	differ	in	Vitamin	D	intake	but	they	differ	in	everything	else	from
population	density,	mitigation	strategies,	and	demographics	to	consumption	of	ice-cream.
One	might	reasonably	counter	that	notwithstanding	any	methodological	concerns,	these	studies
provide	supportive,	suggestive	or	preliminary	evidence	of	the	importance	of	Vitamin	D,	baldness	or	any	of	the
variety	of	other	factors	examined	in	such	a	crude	fashion.	They	don’t,	in	the	same	way	that	a	significant	correlation
between	ice	cream	consumption	and	mortality	rates	from	COVID-19	does	not	provide	any	evidence	in	support	of
the	premise	that	reducing	ice-cream	consumption	can	mitigate	mortality	risk.
One	might	also	reasonably	ask	what	the	harm	here	is,	as	Vitamin	D	is	good	for	you.	Well	it	is	up	to	a	point,	but
there	are	health	risks	associated	with	consuming	too	much	and	if	we	can	imagine	some	people	ingesting	poison	in
order	to	stave	off	the	coronavirus,	it	is	not	hard	to	imagine	some	people	taking	more	Vitamin	D	supplements	than	is
good	for	them.
More	generally,	irrespective	of	any	potential	for	population	harm,	when	research	of	this	nature	is	being	awarded
with	a	publication	and	media	attention,	then	it	makes	it	more	likely	for	other	researchers	to	assume	such	methods
are	an	acceptable	way	to	answer	important	research	questions	and	follow	suit.
To	conclude,	scientists	of	all	disciplinary	backgrounds	have	really	come	to	the	fore	in	this	pandemic.	Indeed,	the
pandemic	highlights	the	importance	of	what	scientists	do.	It	has	been	inspiring	to	see	the	incredible	skill	and
creativity	on	display	from	many	knowledgeable	researchers	in	providing	timely	and	reliable	answers	to	very
complex	questions.	Yet	it	is	incumbent	on	everyone	to	ensure	that	in	the	eagerness	to	provide	timely	and	important
advice,	we	don’t	trade	off	too	much	by	way	of	accuracy	and	reliability.
Of	course	in	the	midst	of	a	pandemic	the	benefits	of	getting	new	information	out	into	the	public	domain	quickly,
particularly	so	when	aimed	at	curing	or	preventing	the	spread	of	a	lethal	virus,	may	outweigh	any	costs	associated
with	providing	less	reliable	information.	Having	said	that,	not	all	research	will	be	critical	to	managing	the	risks	of	the
disease	and	scientists	need	to	ensure	as	best	they	can	that	they	get	this	balance	right.
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